中危AML患者CR1期是首选化疗还是异基因造血干细胞移植?

[1]	Döhner H,Estey EH,Amadori S,et al.Diagnosis and management of acute myeloid leukemia in adults:recommendations from an international expert panel,on behalf of the European LeukemiaNet[J].Blood,2010,115:453-474.
[2]	Patel JP,Gönen M,Figueroa ME,et al.Prognostic relevance of integrated genetic profiling in acute myeloid leukemia[J].N Engl J Med,2012,366:1079-1089.
[3]	Kihara R,Nagata Y,Kiyoi H,et al.Comprehensive analysis of genetic alterations and their prognostic impacts in adult acute myeloid leukemia patients[J].Leukemia,2014,28:1586-1595.
[4]	SEER Cancer Statistics,National Cancer Institute,USA 2002-2006.Available at http://seer.cancer.gov/statfacts/html/amyl.html.
[5]	Döhner K,Paschka P.Intermediate-risk acute myeloid leukemia therapy:current and future[J].Hematology Am Soc Hematol Educ Program,2014,2014:34-43.
[6]	Chen X,Xie H,Wood BL,et al.Relation of clinical response and minimal residual disease and their prognostic impact on outcome in acute myeloid leukemia[J].J Clin Oncol,2015,33:1258-1264.
[7]	Buccisano F,Maurillo L,Del Principe MI,et al.Prognostic and therapeutic implications of minimal residual disease detection in acute myeloid leukemia[J].Blood,2012,119:332-341.
[8]	NCCN.NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines) Acute myeloid Leukemia (Version2.2019).
[9]	成人急性髓系白血病(非急性早幼粒细胞白血病)中国诊疗指南(2017年版)[J].中华血液学杂志,2017,38(3):177-182.
[10]	Vydra J,Sálek C,Schwarz J,et al.Analysis of Real-world Data on Postremission Therapy for Acute Myeloid Leukemia With Intermediate Risk Cytogenetics in First Complete Remission[J].Clin Lymphoma Myeloma Leuk,2018,18:106-113.
[11]	Mizutani M,Hara M,Fujita H,et al.Comparable outcomes between autologous and allogeneic transplant for adult acute myeloid leukemia in first CR[J].Bone Marrow Transplant,2016,51:645-653.
[12]	Keating A,DaSilva G,Pérez WS,et al.Autologous blood cell transplantation versus HLA-identical sibling transplantation for acute myeloid leukemia in first complete remission:a registry study from the Center for International Blood and Marrow Transplantation Research[J].Haematologica,2013,98:185-192.
[13]	Mizutani M,Takami A,Hara M,et al.Comparison of Autologous and Unrelated Transplants for Cytogenetically Normal Acute Myelogenous Leukemia[J].Biol Blood Marrow Transplant,2017,23:1447-1454.
[14]	Saraceni F,Labopin M,Gorin NC,et al.Matched and mismatched unrelated donor compared to autologous stem cell transplantation for acute myeloid leukemia in first complete remission:a retrospective,propensity score-weighted analysis from the ALWP of the EBMT[J].J Hematol Oncol,2016,9:79.
[15]	Gorin NC,Labopin M,Piemontese S,et al.T-cell-replete haploidentical transplantation versus autologous stem cell transplantation in adult acute leukemia:a matched pair analysis[J].Haematologica,2015,100:558-564.
[16]	Li Z,Liu Y,Wang Q,et al.Autologous Stem Cell Transplantation Is a Viable Postremission Therapy for Intermediate-Risk Acute Myeloid Leukemia in First Complete Remission in the Absence of a Matched Identical Sibling:A Meta-Analysis[J].Acta Haematol,2019,141:164-175.
[17]	魏旭东,艾昊,米瑞华,等.沙利度胺联合干扰素、白细胞介素-2治疗复发难治性急性髓系白血病[J].中华内科杂志,2016,55(11):875-877.
[18]	米瑞华,陈琳,魏旭东,等.干扰素α-1b、白细胞介素-2联合沙利度胺方案干预治疗微小残留病阳性急性髓系白血病的疗效分析[J].中华血液学杂志,2019,40(2):118-123.
[19]	Preussler JM,Meyer CL,Mau LW,et al.Healthcare Costs and Utilization for Patients Age 50 to 64 Years with Acute Myeloid Leukemia Treated with Chemotherapy or with Chemotherapy and Allogeneic Hematopoietic Cell Transplantation[J].Biol Blood Marrow Transplant,2017,23:1021-1028.
[20]	Kurosawa S,Yamaguchi T,Mori T,et al.Patient-reported quality of life after allogeneic hematopoietic cell transplantation or chemotherapy for acute leukemia[J].Bone Marrow Transplant,2015,50:1241-1249.
[21]	Armenian SH,Sun CL,Kawashima T,et al.Long-term health-related outcomes in survivors of childhood cancer treated with HSCT versus conventional therapy:a report from the Bone Marrow Transplant Survivor Study (BMTSS) and Childhood Cancer Survivor Study (CCSS)[J].Blood,2011,118:1413-1420.
[22]	Adhikari J,Sharma P,Bhatt VR.Risk of secondary solid malignancies after allogeneic hematopoietic stem cell transplantation and preventive strategies[J].Future Oncol,2015,11:3175-3185.